TUB.BR Overview

Company Profile

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.

Related stocks

ALK-B.CO

ALK-B.CO • Denmark

ALK-Abelló B A/S

227.4 DKK

7.55B USD 1Y +5.6%

JAZZ

JAZZ • Ireland

Jazz Pharmaceuticals plc

218.42 USD

14.18B USD 1Y +61.5%

ASND

ASND • Denmark

Ascendis Pharma A/S

229.23 USD

15.08B USD 1Y +6%

BANB.SW

BANB.SW • Switzerland

80.05 CHF

7.23B USD 1Y +37.7%

CAMX.ST

CAMX.ST • Sweden

641 SEK

3.82B USD 1Y -8.6%

UCB.BR

UCB.BR • Belgium

203.5 EUR

43.48B USD 1Y -21.4%

LKFT

LKFT • Belgium

Lakefront Biotherapeutics

29.73 USD

1.95B USD 1Y -14.5%

LKFT.AS

LKFT.AS • Belgium

LAKEFRONT BIOTHERAPEUTICS

26.32 EUR

1.93B USD 1Y -13.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Website

https://www.financiere-tubize.be

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

29.4% p.a.

Max Drawdown (5Y)

-39.3%

Sharpe Ratio (5Y)

0.39

Beta Factor

0.40

Size Class

Mid Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

🔴 High valuation risk: Avg P/E of 76.9 (Elevated multiple compression risk)

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (29.4% p.a.).